Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
European Respiratory Journal Conference: European Respiratory Society International Congress, ERS ; 60(Supplement 66), 2022.
Article in English | EMBASE | ID: covidwho-2266831

ABSTRACT

Background: The use of dexamethasone improved the outcome among hospitalized patients with Covid-19 since mid-2020 significantly (Horby et al.). However, there remain concerns about an increase of bacterial and fungal growth especially in critical ill patients. Aims and objectives: Aim of our study was to identify the bacterial and fungal pathogens dependent on the use of dexamethasone as a treatment of COVID-19 patients admitted to the intensive care unit (ICU). Studies show that bacterial and fungal co-infections raised during the pandemic due to increased empirical antibiotic use for COVID-19 pneumonia. The effect of dexamethasone has not been in focus. Method(s): For this study, we included all patients who had a lab-confirmed SARS-CoV-2 infection treated on the ICU. The clinical data was collected onsite in 20 hospitals of the German Helios-network between February 2020 and March 2021 and aligned with corresponding claims data. We performed a univariate and multivariate analyses to identify the impact of dexamethasone versus no dexamethasone on the pathogen profile in bloodstream and respiratory infections. Result(s): Out of 1 776 patients included, 1070 were treated with dexamethasone. Those patients were more likely to have an infection with Staphyloccus spp., Candida spp., E. coli, Klebsiella spp. and multidrug resistant bacteria (MRE) compared to patients without dexamethasone treatment. However, no change in the absolute number of detected pathogens was observed. Conclusion(s): Dexamethasone leads to a shift of bacterial and fungal pathogens in ICU-treated COVID-19 patients. This shift should be considered when empirical antibiotic therapy is administered.

2.
Advances in Sleep Apnea: Detection, Diagnosis and Treatment ; : 161-173, 2021.
Article in English | Scopus | ID: covidwho-1469171

ABSTRACT

Continuous positive airway pressure (CPAP) is the most widely used treatment for obstructive sleep apnea (OSA), and was established four decades ago. An alternative option is to use bilevel ventilation, in order to improve compliance to treatment especially in patients who need a high therapeutic pressure to prevent nocturnal respiratory events. Automatic CPAP or bilevel ventilation are also established among OSA therapeutic choices, and are generally indicated in cases of highly variable therapeutic pressure. The major advances in the field regard OSAS in the context of uncomplicated obesity hypoventilation syndrome (OHS), in which either CPAP or bilevel ventilation yield comparable results, and the increasingly popular use of telemedicine in OSA management. The COVID-19 pandemic has been a major determinant of the shift from traditional clinic-based management to using telemedicine whenever possible. In addition, availability of CPAP data recorded in millions of patients has allowed big-data studies on adherence to CPAP or bilevel ventilation over prolonged periods of time. It can be foreseen that e-Health programs will soon be used for most of the clinical activities in the OSA field. © 2021 Nova Science Publishers, Inc.

SELECTION OF CITATIONS
SEARCH DETAIL